Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Foundation Medicine CDx Test for Lynparza

NEW YORK – Foundation Medicine said on Monday that the US Food and Drug Administration has approved its FoundationOne CDx test as a companion diagnostic for olaparib (AstraZeneca's and Merck's Lynparza) for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer.

The test detects both germline and somatic mutations in BRCA1 and BRCA2 and could help identify more patients who could benefit from Lynparza than tests that only identify germline BRCA mutations, Foundation Medicine said, adding that such tests only detect about half of all BRCA mutations.

FoundationOne CDx, which detects mutations in 324 genes, select gene rearrangements, and genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB), already has FDA approval for use in all solid tumors and incorporates multiple companion diagnostics for a total of 18 FDA-approved targeted therapies.

Foundation Medicine, a subsidiary of Roche, has an ongoing collaboration with AstraZeneca and Merck to develop companion diagnostics for Lynparza in prostate cancer.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.